Cargando…
CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
CD47 is a surface glycoprotein expressed by host cells to impede phagocytosis upon binding to macrophage SIRPα, thereby represents an immune checkpoint known as the “don't-eat-me” signal. However, accumulating evidence shows that solid and hematologic tumor cells overexpress CD47 to escape immu...
Autores principales: | Sun, Jennifer, Chen, Yixuan, Lubben, Berit, Adebayo, Ola, Muz, Barbara, Azab, Abdel Kareem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455363/ https://www.ncbi.nlm.nih.gov/pubmed/34584838 http://dx.doi.org/10.1016/j.lrr.2021.100268 |
Ejemplares similares
-
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
por: Sun, Jennifer, et al.
Publicado: (2022) -
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia
por: Alhallak, Kinan, et al.
Publicado: (2021) -
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020) -
Role of CD47 in Hematological Malignancies
por: Eladl, Entsar, et al.
Publicado: (2020) -
Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)